Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02432326 · ClinicalTrials.gov registry record · Phase 1

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 1
Development phase
147
Enrollment target
11
Study locations

NCT02432326 is a Phase 1 study of Cancer and Advanced Solid Tumors that has completed, run by Sumitomo Pharma America. The registered enrollment target is 147 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02432326, a Phase 1 study of Cancer and Advanced Solid Tumors, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 1
Development phase
147 participants
Enrollment target
11
Study locations

Study Summary

This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.

Conditions Studied

Cancer Advanced Solid Tumors

Interventions

  • DRUG BBI608
  • DRUG BBI503

Study Locations (11)

Texas

  • Texas Oncology - Austin Midtown - Austin
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
  • Texas Oncology - Fort Worth 12th Ave - Fort Worth
  • Texas Oncology, P.A. - San Antonio
  • Texas Oncology, P.A. - San Antonio
  • Texas Oncology - Tyler - Tyler

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Indiana

  • Indiana University Simon Cancer Center - Indianapolis

New York

  • Weill Cornell Medical College - New York

Virginia

  • Virginia Cancer Specialists, PC - Fairfax

Washington

  • Northwest Cancer Specialists, PC - Vancouver

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2015-04
Est. Completion 2020-04
Phase Phase 1

Sponsor

Sumitomo Pharma America

168 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02432326

The ClinicalTrials.gov registry entry for NCT02432326 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which BBI608 is the first listed.

NCT02432326 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Texas, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT02432326 about?

NCT02432326 is a clinical study titled "A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors". This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors. The primary goal is to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.

What is the current status of trial NCT02432326?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2015-04. Estimated completion is 2020-04.

What conditions does trial NCT02432326 study?

This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors.

What interventions are being tested in trial NCT02432326?

The interventions under investigation include: BBI608 (DRUG), BBI503 (DRUG).

Who is sponsoring clinical trial NCT02432326?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02432326 being conducted?

This trial has 11 study locations across Illinois, Indiana, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Advanced Solid Tumors

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.